Biocircuits Begins to Deliver
It took longer than expected, but Biocircuits finally filed a 510k application for its doctor’s office immunoassay system and two tests. But will managed care encourage or discourage alternate site testing?
You may also be interested in...
Effective medical device regulation supports both safety and innovation needs. This article assesses how well the US FDA and the Australian TGA achieve this balance.
GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.